9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 126Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: I227|2016-002286-60Study First Received: May 24, 2016Last Updated: March 27, 2017Estimated Primary Completion Date: May 2019Primary Outcome Measures:Progression free survival measured as time from randomization to first observation of objective disease relapse or progression|Number and severity of adverse events|Overall Survival|Quality of Life using EORTC QLQ-C30|Response rate compared using Fisher's exact testSponsors and Collaborators:Canadian Cancer Trials Group|National Cancer Institute, Naples|Merck Sharp & Dohme Corp.Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02784171...

Continue reading

Autologous Dendritic Cell Vaccination in Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 20Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: CCRG13-002Study First Received: December 7, 2015Last Updated: January 24, 2017Estimated Primary Completion Date: October 2020Primary Outcome Measures:Number of MPM patients with feasible and safe DC vaccine production|Number of patients receiving investigational DC vaccine administration combined with standard of care chemotherapy within the proposed time frame|Objective clinical responses by tumor evaluation (clinical efficacy)|Overall survival (clinical efficacy)|Systemic immunogenicity|Local immunogenicitySponsors and Collaborators:University Hospital, AntwerpResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02649829...

Continue reading

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

ConditionMesotheliomaEstimated Enrollment: 600Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: CA209-743|2016-001859-43Study First Received: August 31, 2016Last Updated: April 17, 2017Estimated Primary Completion Date: October 2020Primary Outcome Measures:Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Composite correlation of PD-L1 expression level and efficacySponsors and Collaborators:Bristol-Myers Squibb|Ono Pharmaceutical Co. LtdResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02899299...

Continue reading

MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 50Age Group: Child, Adult, SeniorGender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: MARS2Study First Received: December 20, 2013Last Updated: April 12, 2016Estimated Primary Completion Date: May 2017Primary Outcome Measures:Ability to randomise 50 patients|Survival from the time point of randomisation|Quality of life as assessed using QLQ 30 and LC-13 scalesSponsors and Collaborators:Royal Brompton & Harefield NHS Foundation Trust|Cancer Research UK|Papworth Hospital NHS Foundation TrustResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02040272...

Continue reading

Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers

ConditionLung Cancer|MesotheliomaEstimated Enrollment: 2000Age Group: 30 Years to 85 Years   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Case ControlStudy ID Numbers: Asbestos Screening StudyStudy First Received: September 12, 2005Last Updated: March 17, 2016Estimated Primary Completion Date: March 2017Primary Outcome Measures:Sponsors and Collaborators:University Health Network, TorontoResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00188890...

Continue reading

Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2 Therapy Following Cyclophosphamide and Fludarabine in Patients With Pleural Mesothelioma

ConditionPleural MesotheliomaEstimated Enrollment: 10Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: TILs-003-MesoStudy First Received: April 8, 2015Last Updated: May 31, 2016Estimated Primary Completion Date: June 2025Primary Outcome Measures:Total number of adverse events for each event reported and the severity and attribution to study therapy of each event|Percentage of patients with a clinical response to the study treatmentSponsors and Collaborators:University Health Network, TorontoResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02414945...

Continue reading

CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 336Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: TreatmentStudy ID Numbers: 22864|2016-003111-35|CA290841|A21400Study First Received: February 10, 2017Last Updated: April 11, 2017Estimated Primary Completion Date: June 2021Primary Outcome Measures:Overall survival|modified RECIST or RECIST 1.1 - progression free survival|modified RECIST or RECIST 1.1 - overall response rate|EQ-5D-5L|CTCAE V4.03|Health resource use questionnaireSponsors and Collaborators:University of Southampton|University of Leicester|University of Sheffield|Queen Mary University of London|Queen's University, Belfast|Velindre NHS Trust|Beatson West of Scotland Cancer CentreResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT03063450...

Continue reading

Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 6Age Group: 18 Years to 75 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: 2014_01|2015-001554-15Study First Received: January 14, 2016Last Updated: February 1, 2017Estimated Primary Completion Date: November 2017Primary Outcome Measures:Number of Patients having the full multimodal treatment without unacceptable and unexpected toxicities (grade ≥ 3) graded According to NCI CTC Version 4.0|Number of responders or stable patients after surgery|Progression-free survival (PFS)|Quality of life assessed by a specific questionnaire MPM (HCCA EORTC-30)Sponsors and Collaborators:University Hospital, Lille|Institut National de la Santé Et de la Recherche...

Continue reading

Intrapleural Cryotherapy for Malignant Pleural Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 15Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 14-008715Study First Received: May 14, 2015Last Updated: December 20, 2016Estimated Primary Completion Date: June 2017Primary Outcome Measures:Number of Participants with Adverse Events|Mean Number of Tumor Infiltrating Immune Cells as Measured by Immunohistochemistry on Participant Tissue SamplesSponsors and Collaborators:Mayo Clinic|CSA Medical, Inc.Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02464904...

Continue reading

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma

ConditionAdvanced Malignant Pleural MesotheliomaEstimated Enrollment: 100Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentStudy ID Numbers: NGR019|2010-023614-31Study First Received: May 19, 2011Last Updated: May 27, 2016Estimated Primary Completion Date: December 2016Primary Outcome Measures:Progression-Free Survival (PFS)|Overall survival (OS)|Tumor response|Safety and Toxicity according to NCI-CTCAE criteria(version 4.03)|Quality of life (QoL) according to Lung Cancer Symptom ScaleSponsors and Collaborators:MolMed S.p.A.Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01358084...

Continue reading